Comparative Efficacy and Strategic Sequencing of CAR-T Therapy, Blinatumomab, and Inotuzumab Ozogamicin in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemiad: A Systematic Review and Meta-Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #ALL-725; Location: LEVEL 3, HALL B3; "CAR-T therapy offers superior durability, while inotuzumab provides the most potent cytoreduction for high-burden disease. Blinatumomab is optimal for MRD-positive, low-burden states. Optimal management requires a personalized sequence: using inotuzumab or blinatumomab as a bridge to transplant or CAR-T therapy to maximize long-term, leukemia-free survival."
CAR T-Cell Therapy • Retrospective data • Review • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology
|
|
Divyanshu Kumar 1; Rishita Verma 2; Rajesh Veeramachaneni 3; Sourav Hazra 4; Rakhshanda Khan 5; Harshawardhan Dhanraj Ramteke 6; Dineshbaba Murugavel 7
|